Kröber Alexander, Seiler Till, Benner Axel, Bullinger Lars, Brückle Elsbeth, Lichter Peter, Döhner Hartmut, Stilgenbauer Stephan
Abteilung Innere Medizin III, University of Ulm, Germany.
Blood. 2002 Aug 15;100(4):1410-6.
In chronic lymphocytic leukemia (CLL), biologic risk factors such as immunoglobulin variable heavy chain gene (V(H)) mutation status, CD38 expression level, and genomic aberrations have recently been identified, but the relative prognostic impact of the individual parameters is unknown. In the current study, we analyzed V(H) mutation status by polymerase chain reaction and sequencing (n = 300), genomic aberrations by fluorescence in situ hybridization (+3q, 6q-, +8q, 11q-, +12q, 13q-, t(14q), 17p-) (n = 300), and CD38 expression by triple-color FACS (CD5, CD19, CD38) (n = 157) in a unicentric CLL cohort. The prognostic influence of V(H) mutation rate and CD38 expression level was tested by maximally selected log-rank statistics. A corrected P value (P(cor)) for a cutoff level allowing the best separation of 2 subgroups with different survival probabilities was identified at 97% V(H) homology (95% confidence interval [CI], 96%-98% homology, P(cor) <.001) and at 7% CD38 expression (95% CI, 20%-71% expression, P(cor) =.02). In univariate analyses, unmutated V(H) genes and high CD38 expression levels predicted for shorter survival times. The overall incidence of genomic aberrations was similar in the V(H) unmutated and V(H) mutated subgroups. High-risk genomic aberrations such as 17p- and 11q- occurred almost exclusively in the V(H) unmutated subgroup, whereas favorable aberrations such as 13q- and 13q- as single abnormalities were overrepresented in the V(H) mutated subgroup. In multivariate analysis, unmutated V(H), 17p deletion, 11q deletion, age, WBC, and LDH were identified as independent prognostic factors, indicating a complementary role of V(H) mutation status and genomic aberrations to predict outcome in CLL.
在慢性淋巴细胞白血病(CLL)中,近期已确定了一些生物学危险因素,如免疫球蛋白可变重链基因(V(H))突变状态、CD38表达水平和基因组畸变,但各参数的相对预后影响尚不清楚。在本研究中,我们在一个单中心CLL队列中,通过聚合酶链反应和测序分析了V(H)突变状态(n = 300),通过荧光原位杂交分析了基因组畸变(+3q、6q-、+8q、11q-、+12q、13q-、t(14q)、17p-)(n = 300),并通过三色流式细胞术(CD5、CD19、CD38)分析了CD38表达(n = 157)。通过最大选择对数秩统计检验V(H)突变率和CD38表达水平的预后影响。在V(H)同源性为97%(95%置信区间[CI],96%-98%同源性,校正P值[P(cor)]<.001)和CD38表达为7%(95%CI,20%-71%表达,P(cor)=.02)时,确定了一个截止水平的校正P值,该水平能最佳区分具有不同生存概率的两个亚组。在单变量分析中,V(H)基因未突变和CD38高表达水平预示生存时间较短。V(H)未突变和V(H)突变亚组中基因组畸变的总体发生率相似。高危基因组畸变如17p-和11q-几乎仅发生在V(H)未突变亚组,而有利的畸变如13q-作为单一异常在V(H)突变亚组中过度存在。在多变量分析中,V(H)未突变、17p缺失、11q缺失、年龄、白细胞和乳酸脱氢酶被确定为独立的预后因素,表明V(H)突变状态和基因组畸变在预测CLL预后方面具有互补作用。